Cellebrite DI Future Growth
Future criteria checks 5/6
Cellebrite DI is forecast to grow earnings and revenue by 83.3% and 15.3% per annum respectively. EPS is expected to grow by 110.1% per annum. Return on equity is forecast to be 21% in 3 years.
Key information
83.3%
Earnings growth rate
110.1%
EPS growth rate
Software earnings growth | 17.0% |
Revenue growth rate | 15.3% |
Future return on equity | 21.0% |
Analyst coverage | Good |
Last updated | 11 Mar 2025 |
Recent future growth updates
Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 16Recent updates
Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 16Cellebrite DI: Attractive Company In Connection With AI And Digital Investigation
Feb 04A Look At The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)
Jan 10Cellebrite: There Are Potential Risks That Could Damper Growth
Nov 08Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?
Oct 30There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased
Sep 10Cellebrite: Rating Downgrade As Valuation Has Caught Up
Aug 27Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up
Aug 17Why We're Not Concerned About Cellebrite DI Ltd.'s (NASDAQ:CLBT) Share Price
Jun 25Is Cellebrite DI Ltd. (NASDAQ:CLBT) Potentially Undervalued?
May 21Cellebrite: Big Fish In A Small Pond
Apr 29Cellebrite DI Ltd.'s (NASDAQ:CLBT) P/S Is Still On The Mark Following 28% Share Price Bounce
Mar 14Cellebrite DI Ltd. (NASDAQ:CLBT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$13.17
Feb 18There's Reason For Concern Over Cellebrite DI Ltd.'s (NASDAQ:CLBT) Price
Jan 28Is Cellebrite DI Ltd. (NASDAQ:CLBT) Trading At A 39% Discount?
Nov 04Calculating The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)
May 26We Ran A Stock Scan For Earnings Growth And Cellebrite DI (NASDAQ:CLBT) Passed With Ease
Apr 29Is Now The Time To Look At Buying Cellebrite DI Ltd. (NASDAQ:CLBT)?
Mar 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 669 | 113 | 211 | 220 | 4 |
12/31/2026 | 578 | 91 | 178 | 185 | 8 |
12/31/2025 | 484 | 74 | 147 | 157 | 8 |
12/31/2024 | 401 | -283 | 122 | 132 | N/A |
9/30/2024 | 385 | -317 | 99 | 110 | N/A |
6/30/2024 | 362 | -103 | 87 | 98 | N/A |
3/31/2024 | 343 | -112 | 91 | 100 | N/A |
12/31/2023 | 325 | -81 | 94 | 102 | N/A |
9/30/2023 | 306 | -64 | 88 | 94 | N/A |
6/30/2023 | 294 | -42 | 57 | 64 | N/A |
3/31/2023 | 280 | 20 | 36 | 44 | N/A |
12/31/2022 | 271 | 116 | 11 | 21 | N/A |
9/30/2022 | 265 | 165 | 8 | 15 | N/A |
6/30/2022 | 259 | 152 | 1 | 7 | N/A |
3/31/2022 | 255 | 122 | 17 | 26 | N/A |
12/31/2021 | 246 | 70 | 28 | 36 | N/A |
9/30/2021 | 236 | 7 | 30 | 38 | N/A |
6/30/2021 | 223 | 7 | 55 | 63 | N/A |
3/31/2021 | 209 | 2 | 66 | 72 | N/A |
12/31/2020 | 195 | -9 | 60 | 67 | N/A |
12/31/2019 | 172 | -10 | 10 | 16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLBT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: CLBT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CLBT is expected to become profitable in the next 3 years.
Revenue vs Market: CLBT's revenue (15.3% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CLBT's revenue (15.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLBT's Return on Equity is forecast to be high in 3 years time (21%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/14 07:30 |
End of Day Share Price | 2025/03/14 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cellebrite DI Ltd. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Tomer Zilberman | BofA Global Research |
Tyler Radke | Citigroup Inc |
Jeffrey Van Rhee | Craig-Hallum Capital Group LLC |